Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,385
- 试验地点
- 1
- 主要终点
- Estimated Number of US Patients Eligible for Inclisiran Treatment
研究概览
简要总结
The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and Nutrition Examination Survey (NHANES) data and inclisiran eligibility criteria from ongoing clinical trials as well as to estimate the number of preventable ASCVD events based on expected risk reductions from the degree of low-density lipoprotein cholesterol (LDL-C) lowering expected from inclisiran.
This study used data from the US NHANES 2011-2020 surveys. NHANES is a national survey which collects medical history, laboratory, and medication information from participants of all ages.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Estimated Number of US Patients Eligible for Inclisiran Treatment
时间窗: 10 years
Estimated Number of Preventable Cardiovascular Events Over 10-years of Inclisiran Treatment
时间窗: 10 years
次要结局
未报告次要终点